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Chronic inflammatory fibro-proliferative changes leading to atherosclerotic plaques 
are considered hallmark of cardiovascular diseases [1]. Atherosclerosis pathogenesis is a 
complex entity, which has not been fully understood; however, many studies have demon-
strated the role of oxidative stress and inflammation in its development. Melatonin effects 
on inflammation and oxidative stress process have been demonstrated in the last ten-year 
literature [2]. However, its role(s) and mechanism(s) of action as a therapeutic tool against 
atherosclerosis remain largely unexplored. Our aims were to assess the role of melatonin 
in the onset and developing of atherosclerotic plaques through radiologic and morpho-
metrical tools in 20 apolipoprotein-E knockout (ApoE) mice fed with Western diet (42% 
calories from fat). 10/20 mice were treated with melatonin (10 mg/kg per os). 18F-FDG 
PET-CT is a widely used tool to assess inflammatory changes, even before macroscopic 
changes have taken place. Glucose metabolism is known to be higher in areas of inflam-
mation due to an increased expression of GLUT transporters on the cell membranes both 
in animals and humans. Using this feature PET/CT is able to determinate metabolic cel-
lular changes and therefore it can be used as biomarker of atherosclerosis. All mice were 
scanned both before starting melatonin treatment and at the end of the study. After the 
last scan mice were sacrificed and vascular remodeling, oxidative stress and inflammation 
at aortic arch level were evaluated. CT-corrected PET datasets were used for computation 
of SUVmax. 
Atherosclerotic vascular remodeling, oxidative stress and inflammation levels were sig-
nificantly more conspicuous in the control cohort, compared to the treated mice (p≤0.05). 
18F-FDG PET/CT did not show significant difference in SUVmax. In summary, also in 
vivo, melatonin may have a protective effect in the atherosclerotic pathogenesis. 
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cial supports: Fondazione Cariplo e Regione Lombardia “New opportunities and ways 
towards ERC” (Project 2014-2256) and University of California - Radiology and Biomedi-
cal Imaging Nuclear Medicine Section. 
References
[1] Badimon et al. (2010) Nutraceuticals and atherosclerosis: human trials. Cardiovasc Ther 28: 202-
215.
[2] Favero et al. (2014) Melatonin and its atheroprotective effects: a review. Mol Cell Endocrinol. 382: 
926-937.
Keywords
Atherosclerosis, inflammation, melatonin, oxidative stress, 18F-FDG PET.
